
Opinion|Videos|July 13, 2024
Highlights from ASCO 2024: Individualized Neoantigen Therapy in Melanoma
Considerations for neoantigen therapy tailored to specific patient needs is discussed by Dr Lipson.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Discuss the 3-year updated data presented at ASCO 2024 on individualized neoantigen therapy (mRNA-4157) plus pembrolizumab in resected melanoma.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- Please provide your key takeaways from this study. How might these findings impact the management of patients with melanoma?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
5 Consequences If ACA Premium Subsidies End in 2026
2
Raludotatug Deruxtecan Demonstrates Promising Efficacy, Safety in Platinum-Resistant Ovarian Cancer
3
Age-Related Disparities in ADC Treatment Rates in Breast Cancer with Tabby Khan, MD
4
Culturally Competent Menopause Care: Lisa Taylor-Swanson, PhD
5














































